Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1072

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

Interventions

COMBINATION_PRODUCT: Anifrolumab
COMBINATION_PRODUCT: Anifrolumab
DRUG: Anifrolumab

Sponsor

AstraZeneca